Braveheart Bio filed for a Nasdaq listing, setting up an IPO path for its oral cardiac myosin inhibitor program BHB-1893 in hypertrophic cardiomyopathy. The company said it will use proceeds to advance the asset, which came from a licensing agreement with Jiangsu Hengrui Pharmaceuticals and has Phase 2 data across obstructive and nonobstructive HCM subtypes.